Exact Mass: 508.24677660000003
Exact Mass Matches: 508.24677660000003
Found 71 metabolites which its exact mass value is equals to given mass value 508.24677660000003,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
Argatroban
C23H36N6O5S (508.24677660000003)
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban. D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
PD 123319
C31H32N4O3 (508.24742819999994)
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Argatroban
C23H36N6O5S (508.24677660000003)
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AE - Direct thrombin inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
C31H32N4O3 (508.24742819999994)
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
Kushenol M
Kushenol M is a natural product found in Sophora flavescens with data available.
Tanariflavanone A
A hydroxyflavanone with a pyranochromane skeleton that is 3,4,7,8-tetrahydro-2H,6H-pyrano[3,2-g]chromen-6-one substituted by geminal methyl groups at position 2, hydroxy groups at positions 3 and 5 and a phenyl group at position 8 which in turn is substituted by a geranyl group at position 2 and hydroxy groups at positions 3 and 4. Isolated from Macaranga tanarius, it exhibits alleopathic effect.
Petalostemumol
Tanariflavanone C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5,7, 3 and 4, a geranyl group at position 2 and a 2-hydroxy-3-methylbut-3-en-1yl group at position 6. Isolated from Macaranga tanarius, it exhibits radical scavenging activity.
(12R)-12-cinnamoyloxy-3beta,5-dihydroxy-8,14-seco-5beta,17beta-pregn-6-ene-8,14,20-trione|cynaphyllogenin|Cynaphylloside
(-)-(7S,7S,8R,8S,8R)-4,4-dihydroxy-3,3,5-trimethoxy-4,8-oxy-2,7-cyclo-8,8-sesquineolignan-7-ol
A neolignan isolated from the barks of Machilus robusta.
(E)-2,3-dihydro-4-hydroxy-2-(1-hydroxy-1-methylethyl)-7,8-dimethoxy-6-(3,7-dimethyl-2,6-octadienyl)-5H-furo[3,2-b]xanthen-5-one|oliverixanthone
Argatroban Impurity 26
C23H36N6O5S (508.24677660000003)
(6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
C31H32N4O3 (508.24742819999994)
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(8-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-6-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H-1-benzopyran-4-one
1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
C31H32N4O3 (508.24742819999994)
D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents
5-(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-1h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(1r,3br,4s,5r,5ar,9as,9br,11as)-4-(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-1h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
{3-hydroxy-4-[(2s)-2-hydroxy-6-methylheptan-2-yl]phenyl}methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate
2-[3,4-dihydroxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
[(5ar,7ar,8r,9s,11as,11br)-9-(acetyloxy)-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate
(2s)-2-[(2s)-2-[(1-hydroxyethylidene)amino]-n-methyl-3-phenylpropanamido]-n-[(1z)-2-(1h-indol-3-yl)ethenyl]-3-phenylpropanimidic acid
C31H32N4O3 (508.24742819999994)
(5s,12r)-5-{2-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,4-dihydroxyphenyl}-9,12-dihydroxy-13,13-dimethyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-trien-7-one
(2r,3r)-2-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxyphenyl}-3,5,7-trihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(3as,6s,8s,9r,9as,9bs)-6,9-dihydroxy-6,9-dimethyl-3-methylidene-2-oxo-3ah,4h,5h,8h,9ah,9bh-azuleno[4,5-b]furan-8-yl 2-[(2r,4as,8ar)-4a-methyl-8-methylidene-7-oxo-2,3,4,8a-tetrahydro-1h-naphthalen-2-yl]prop-2-enoate
(2s)-2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(2-hydroxy-3-methylbut-3-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(3r)-2-[3,4-dihydroxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-{2-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,4-dihydroxyphenyl}-5,7-dihydroxy-6-[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]-2,3-dihydro-1-benzopyran-4-one
6-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-4-hydroxy-2-(2-hydroxypropan-2-yl)-7,8-dimethoxy-2h,3h-furo[3,2-b]xanthen-5-one
[9-(acetyloxy)-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate
(2r,3r)-2-[3,4-dihydroxy-2,6-bis(3-methylbut-2-en-1-yl)phenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
[3-hydroxy-4-(2-hydroxy-6-methylheptan-2-yl)phenyl]methyl 2-hydroxy-4-(3-hydroxy-5-methylphenoxy)-6-methylbenzoate
[(5ar,7as,8r,9r,11ar,11bs)-9-(acetyloxy)-5a,8,11a-trimethyl-1-oxo-3-phenyl-6,7,7a,9,10,11,11b,12-octahydro-2,5-dioxatetraphen-8-yl]methyl acetate
2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(2-hydroxy-3-methylbut-3-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
2,7,12,13'-tetramethyl-4',5,10,14',16'-pentaoxaspiro[pentacyclo[10.2.2.0¹,¹¹.0⁴,⁸.0⁹,¹¹]hexadecane-14,6'-tetracyclo[11.2.1.0¹,¹⁰.0³,⁷]hexadecane]-9',15-diene-5',6-dione
(1r,3br,4s,5r,5ar,9br,11as)-4-(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-2,7-dioxo-1h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
2,27-dihydroxy-6,10,15,20,20-pentamethyl-8,12,21-trioxaheptacyclo[13.13.0.0²,¹¹.0⁴,⁹.0¹¹,¹³.0¹⁶,²⁷.0¹⁹,²⁵]octacosa-3,5,23,25-tetraene-7,22-dione
(2s)-5,7-dihydroxy-8-[(2s)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-6-(3-methylbut-2-en-1-yl)-2-(2,4,6-trihydroxyphenyl)-2,3-dihydro-1-benzopyran-4-one
5-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-9,12-dihydroxy-13,13-dimethyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-trien-7-one
(2s)-2-[(2s)-2-[(1-hydroxyethylidene)amino]-n-methyl-3-phenylpropanamido]-n-[(1e)-2-(1h-indol-3-yl)ethenyl]-3-phenylpropanimidic acid
C31H32N4O3 (508.24742819999994)